Serum interleukin-8 and insulin like growth factor-1 in Egyptian bladder cancer patients

Cancer Biomark. 2010;6(2):105-10. doi: 10.3233/CBM-2009-0133.

Abstract

Background: Bladder cancer is a major health problem in Egypt as it represents the most common malignancy.

Aim: Evaluation of the potential usefulness of serum IL-8 and IGF-1 in Egyptian bladder cancer patients.

Methods: Serum levels of IL-8 and IGF-1 were determined in 51 bladder cancer patients and 45 controls using a chemiluminescence enzyme immunometric assay.

Results: Serum IL-8 was significantly higher in cancer patients than in controls (P < 0.0001). It was significantly higher in patients with invasive cancer than those with superficial cancer (P < 0.01). Also, IL-8 showed a significant elevation in relation to schistosomal infection (P = 0.02) however, it did not differ in relation to either pathological type of tumor or its grade (P > 0.05). Receiver operating characteristic (ROC) curve indicated that IL-8 cut-off value of 35 pg/mL yielded the best combination of sensitivity (71%) and specificity (98%) for differentiating patients with bladder cancer from control subjects. Serum IGF-1 levels showed no significant difference between bladder cancer patients and controls (P > 0.05). There was no relationship between IGF-1 levels and clinicopathological parameters.

Conclusions: In Egyptian patients with bladder cancer, serum IL-8 is significantly elevated and its level is related to tumor invasion and associated schistosomal infection. Moreover, serum IGF-1 level does not help as a serum tumor marker in these patients.

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood*
  • Egypt
  • Female
  • Humans
  • Insulin-Like Growth Factor I / analysis*
  • Interleukin-8 / blood*
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Schistosomiasis / complications
  • Urinary Bladder Neoplasms / blood
  • Urinary Bladder Neoplasms / complications
  • Urinary Bladder Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • Interleukin-8
  • Insulin-Like Growth Factor I